MYND Life Sciences Inc. (MYNDF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.82 Million CAD | 40.97% |
| 2022 | -2.98 Million CAD | 28.92% |
| 2021 | -4.28 Million CAD | 0.0% |
| 2020 | - CAD | 0.0% |
| 2019 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -341.69 Thousand CAD | -54.91% |
| 2024 Q2 | -220.57 Thousand CAD | 33.91% |
| 2024 Q1 | -333.77 Thousand CAD | 13.9% |
| 2023 Q4 | -387.65 Thousand CAD | -23.64% |
| 2023 FY | - CAD | 40.97% |
| 2023 Q3 | -313.53 Thousand CAD | 26.91% |
| 2023 Q2 | -428.97 Thousand CAD | 32.36% |
| 2023 Q1 | -634.25 Thousand CAD | -29.29% |
| 2022 Q2 | -702.22 Thousand CAD | 38.0% |
| 2022 Q1 | -1.13 Million CAD | 28.08% |
| 2022 FY | - CAD | 28.92% |
| 2022 Q4 | -490.57 Thousand CAD | 26.9% |
| 2022 Q3 | -671.12 Thousand CAD | 4.43% |
| 2021 Q2 | -741.97 Thousand CAD | 36.38% |
| 2021 Q4 | -1.57 Million CAD | -92.66% |
| 2021 Q3 | -817.44 Thousand CAD | -10.17% |
| 2021 FY | - CAD | 0.0% |
| 2021 Q1 | -1.16 Million CAD | 0.0% |
| 2020 FY | - CAD | 0.0% |
| 2019 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 97.431% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 69.215% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.154% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 89.492% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.941% |
| Mesoblast Limited | -62.38 Million USD | 97.075% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -18.824% |
| Genus plc | 73.7 Million USD | 102.477% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 72.394% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 48.543% |
| Marizyme, Inc. | -34.28 Million USD | 94.676% |
| ContraFect Corporation | -64.99 Million USD | 97.192% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 79.193% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 59.675% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -30.203% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 30.98% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 21.457% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -252.323% |
| Accustem Sciences Inc. | -3.74 Million USD | 51.282% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 96.215% |
| EV Biologics, Inc. | -1.26 Million USD | -44.042% |
| Q BioMed Inc. | -617.62 Thousand USD | -195.517% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 151.097% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -188.611% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 20.105% |
| Biomind Labs Inc. | -1.03 Million USD | -76.424% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 118.479% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 74.513% |
| Skye Bioscience, Inc. | -13.54 Million USD | 86.527% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -22.71% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -7200.784% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 53.011% |
| IMV Inc. | -35.52 Million USD | 94.862% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 88.499% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 27.049% |
| GB Sciences, Inc. | -1.41 Million USD | -28.545% |
| Alpha Cognition Inc. | -9.7 Million USD | 81.194% |
| HST Global, Inc. | -5303.00 USD | -34318.178% |
| CSL Limited | 4.78 Billion USD | 100.038% |
| Halberd Corporation | -74.27 Thousand USD | -2357.217% |
| Enzolytics Inc. | -2.12 Million USD | 13.988% |
| Resverlogix Corp. | -11.74 Million USD | 84.456% |
| Affymax, Inc. | -14.29 Million USD | 87.232% |
| SYBLEU INC | -141.57 Thousand USD | -1189.244% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 40.412% |
| argenx SE | -216.02 Million USD | 99.155% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 96.702% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 249.975% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -21.769% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 581.78% |
| AVAX Technologies, Inc. | -6.11 Million USD | 70.141% |
| Zenith Capital Corp. | -8.6 Million USD | 78.792% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.266% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -10376.988% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 25.394% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -936.9% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 95.395% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 36.895% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -74.441% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 27244.497% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -4.297% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 4.983% |
| BioStem Technologies, Inc. | -7.55 Million USD | 75.837% |
| ONE Bio Corp. | 13.61 Million USD | 113.408% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -907.906% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 11.269% |
| Agentix Corp. | -1.37 Million USD | -33.055% |
| LadRx Corporation | 412.28 Thousand USD | 542.705% |
| Cell Source, Inc. | -4.27 Million USD | 57.281% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -397.029% |
| Regen BioPharma, Inc. | 1.46 Million USD | 224.506% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -94.802% |
| NovAccess Global Inc. | -1.03 Million USD | -76.382% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 120.615% |
| Itoco Inc. | -1.86 Million USD | 2.343% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -380.796% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -63.548% |
| Kadimastem Ltd | -2.62 Million USD | 30.452% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -663.201% |
| CytoDyn Inc. | -18.02 Million USD | 89.876% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -2209.527% |
| Mobile Lads Corp. | -2.24 Million USD | 18.56% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -14825.145% |
| Qrons Inc. | -40.08 Thousand USD | -4453.769% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -275.804% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 446.053% |
| Rebus Holdings, Inc. | -951 Thousand USD | -91.924% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -71.862% |
| International Stem Cell Corporation | 202 Thousand USD | 1003.562% |
| Bioxytran, Inc. | -3.82 Million USD | 52.222% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -3367.318% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 25.863% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 94.911% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -3955.991% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 33.338% |
| Neutra Corp. | -181.24 Thousand USD | -907.021% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 90.946% |
| PureTech Health plc | -11.62 Million USD | 84.302% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 90.945% |
| IXICO plc | -707 Thousand USD | -158.161% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 76.25% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 96.225% |
| CSL Limited | 4.73 Billion USD | 100.039% |
| Cellectis S.A. | -92.63 Million USD | 98.03% |